GNbAC1, a Humanized Monoclonal Antibody Against the Envelope Protein of Multiple Sclerosis-Associated Endogenous Retrovirus: A First-in-Humans Randomized Clinical Study

Clinical Therapeutics

Volumn 34, Issue 12, 2012, Pages 2268-2278

  Curtin, François ^a   Lang, Alois B ^a   Perron, Hervé ^a   Laumonier, Marion ^a   Vidal, Virginie ^a   Porchet, Hervé C ^a   Hartung, Hans Peter ^b  

^a GENEURO SA   (Switzerland)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GNBAC1; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BURN; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EMOTIONAL STRESS; ENDOGENOUS RETROVIRUS; FLU LIKE SYNDROME; GASTROENTERITIS; HUMAN; IMMUNOGENICITY; INFECTION; JAW PAIN; LEUKOPENIA; LIMB PAIN; MALE; MULTIPLE SCLEROSIS ASSOCIATED RETROVIRUS; NAUSEA; NORMAL HUMAN; OROPHARYNX PAIN; PARAMETERS; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOGENOUS RETROVIRUSES; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; VIRAL ENVELOPE PROTEINS;

EID: 84870762817     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.11.006     Document Type: Article

References (18)

1. Lassmann H., Bruck W., Lucchinetti C.F. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007, 17:210-218.
2. Spain R.I., Cameron M.H., Bourdette D. Recent developments in multiple sclerosis therapeutics. BMC Med 2009, 7:74.
3. Perron H., Geny C., Laurent A., et al. Leptomeningeal cell line from multiple sclerosis with reverse transcriptase activity and viral particles. Res Virol 1989, 140:551-561.
4. Perron H., Lalande B., Gratacap B., et al. Isolation of retrovirus from patients with multiple sclerosis. Lancet 1991, 337:862-863.
5. Perron H., Garson J.A., Bedin F., et al. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. Proc Natl Acad Sci U S A 1997, 94:7583-7588. Collaborative Research Group on Multiple Sclerosis.
6. Sotgiu S., Mameli G., Serra C., et al. Multiple sclerosis-associated retrovirus and progressive disability of multiple sclerosis. Mult Scler 2010, 16:1248-1251.
7. Mameli G., Astone V., Arru G., et al. Brains and peripheral blood mononuclear cells of multiple sclerosis (MS) patients hyperexpress MS-associated retrovirus/HERV-W endogenous retrovirus, but not Human herpesvirus 6. J Gen Virol 2007, 88(Pt 1):264-274.
8. Perron H., Germi R., Bernard C., et al. Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler 2012, [in press].
9. Firouzi R., Rolland A., Michel M., et al. Multiple sclerosis-associated retrovirus particles cause T lymphocyte-dependent death with brain hemorrhage in humanized SCID mice model. J Neurovirol 2003, 9:79-93.
10. Rolland A., Jouvin-Marche E., Viret C., et al. The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and promotes Th1-like responses. J Immunol 2006, 176:7636-7644.
11. Kremer D, Schichel T, Bernard C, et al. The role of the multiple sclerosis associated retrovirus (MSRV) envelope protein (ENV) in oligodendroglial homeostasis and differentiation. Presented at: ARSEPsymposium.Paris,France;2011. Poster.
12. Leech S., Kirk J., Plumb J., McQuaid S. Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol Appl Neurobiol 2007, 33:86-98.
13. McLean B.N., Zeman A.Z., Barnes D., Thompson E.J. Patterns of blood-brain barrier impairment and clinical features in multiple sclerosis. J Neurol Neurosurg Psychiatry 1993, 56:356-360.
14. Morell A., Terry W.D., Waldmann T.A. Metabolic properties of IgG subclasses in man. J Clin Invest 1970, 49:673-680.
15. Newsome B.W., Ernstoff M.S. The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?. Br J Clin Pharmacol 2008, 66:6-19.
16. Wang W., Wang E.Q., Balthasar J.P. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008, 84:548-558.
17. Holford N.H. Pharmacokinetics & Pharmacodynamics: Rational Dosing & the Time Course of Drug Action. Basic & Clinical Pharmacology 2004, 34-50. Lange Medical Books/McGraw Hill, New York. 9th ed. B.G. Katzung (Ed.).
18. Keizer R.J., Huitema A.D., Schellens J.H., Beijnen J.H. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010, 49:493-507.